Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Now Covered by TD Cowen

TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a report released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $60.00 target price on the stock.

A number of other research analysts have also issued reports on the company. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 7th. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Buy” and a consensus target price of $44.29.

Kiniksa Pharmaceuticals International Trading Up 6.2%

NASDAQ KNSA opened at $38.77 on Monday. The company has a 50-day moving average price of $33.58 and a two-hundred day moving average price of $28.31. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $38.87. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of 969.49 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $415,147.14. This represents a 86.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ross Moat sold 3,523 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the transaction, the insider owned 9,415 shares of the company’s stock, valued at approximately $332,443.65. This trade represents a 27.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 561,371 shares of company stock valued at $18,825,009 in the last ninety days. 53.48% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. Tower Research Capital LLC TRC raised its position in shares of Kiniksa Pharmaceuticals International by 1,539.1% during the second quarter. Tower Research Capital LLC TRC now owns 25,275 shares of the company’s stock worth $699,000 after purchasing an additional 23,733 shares during the period. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 428.8% during the second quarter. Lazard Asset Management LLC now owns 15,181 shares of the company’s stock valued at $420,000 after purchasing an additional 12,310 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $1,640,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.